Cytarabine

Generic Name
Cytarabine
Brand Names
Cytosar, Vyxeos
Drug Type
Small Molecule
Chemical Formula
C9H13N3O5
CAS Number
147-94-4
Unique Ingredient Identifier
04079A1RDZ
Background

A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication

For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
Associated Therapies
-
Clinical Trials
Related News

Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

First Posted Date
2017-01-12
Last Posted Date
2023-02-16
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
22
Registration Number
NCT03019640
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma

First Posted Date
2017-01-11
Last Posted Date
2017-01-11
Lead Sponsor
Tingbo Liu
Target Recruit Count
50
Registration Number
NCT03016988

Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm

First Posted Date
2017-01-06
Last Posted Date
2022-03-08
Lead Sponsor
University of Washington
Target Recruit Count
50
Registration Number
NCT03012672
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

First Posted Date
2017-01-02
Last Posted Date
2024-12-04
Lead Sponsor
Children's Oncology Group
Target Recruit Count
475
Registration Number
NCT03007147
Locations
🇺🇸

Henry Ford Health Saint John Hospital, Detroit, Michigan, United States

🇺🇸

Children's Hospital of Alabama, Birmingham, Alabama, United States

🇺🇸

USA Health Strada Patient Care Center, Mobile, Alabama, United States

and more 224 locations

Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia

First Posted Date
2016-12-07
Last Posted Date
2016-12-07
Lead Sponsor
Chunyan Ji
Target Recruit Count
30
Registration Number
NCT02985372

Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP

First Posted Date
2016-12-06
Last Posted Date
2018-01-19
Lead Sponsor
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Target Recruit Count
34
Registration Number
NCT02983097
Locations
🇩🇪

LMU Klinikum München-Großhadern, München, Germany

🇩🇪

Diakonie Krankenhaus Bremen, Bremen, Germany

🇩🇪

Universitätsklinikum Heidelberg, Heidelberg, Germany

and more 9 locations

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

First Posted Date
2016-12-05
Last Posted Date
2024-12-04
Lead Sponsor
Children's Oncology Group
Target Recruit Count
80
Registration Number
NCT02981628
Locations
🇺🇸

Children's Hospital of Alabama, Birmingham, Alabama, United States

🇺🇸

Providence Alaska Medical Center, Anchorage, Alaska, United States

🇺🇸

Banner Children's at Desert, Mesa, Arizona, United States

and more 153 locations

Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

First Posted Date
2016-11-23
Last Posted Date
2024-05-06
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
40
Registration Number
NCT02971397
Locations
🇺🇸

Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

First Posted Date
2016-11-06
Last Posted Date
2023-10-10
Lead Sponsor
Philogen S.p.A.
Target Recruit Count
30
Registration Number
NCT02957032
Locations
🇩🇪

Münster University Hospital, Münster, Germany

A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia

First Posted Date
2016-11-03
Last Posted Date
2019-11-21
Lead Sponsor
Pfizer
Target Recruit Count
8
Registration Number
NCT02954653
Locations
🇺🇸

Wake Forest Baptist Health, Winston-Salem, North Carolina, United States

🇺🇸

The University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States

🇺🇸

Banner-University Medical Center Tucson, Tucson, Arizona, United States

and more 1 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy